[EN] CONCISE PROCESS FOR PREPARING 3-PYRROLIDINE CARBOXYLIC ACID DERIVATIVES [FR] PROCÉDÉ CONCIS POUR LA PRÉPARATION DE DÉRIVÉS D'ACIDE 3-PYRROLIDINE CARBOXYLIQUE
Synthesis of pyrrolidine-3-carboxylic acid derivatives <i>via</i> asymmetric Michael addition reactions of carboxylate-substituted enones
作者:Feng Yin、Ainash Garifullina、Fujie Tanaka
DOI:10.1039/c7ob01484h
日期:——
concisely synthesize highly enantiomerically enriched 5-alkylsubstituted pyrrolidine-3-carboxylic acids, organocatalytic enantioselective Michael addition reactions of 4-alkyl-substituted 4-oxo-2-enoates with nitroalkanes have been developed. Using the developed reaction method, 5-methylpyrrolidine-3-carboxylic acid with 97% ee was obtained in two steps.
Revisiting Bromohexitols as a Novel Class of Microenvironment‐Activated Prodrugs for Cancer Therapy
作者:Henrik Johansson、Omar Hussain、Simon J. Allison、Tony V. Robinson、Roger M. Phillips、Daniel Sejer Pedersen
DOI:10.1002/cmdc.201900578
日期:2020.1.17
even subtle changes in stereochemistry. However, no attempts have been made to improve the therapeutic window by rational drug design or by using a prodrug approach to exploit differences between tumour physiology and healthy tissue, such as acidic extracellular pH and hypoxia. Herein, we report the photochemical synthesis of highly substituted endoperoxides as key precursors for dibromohexitol derivatives
NOVEL PYRIDINE CARBOXYLIC ACID BASED COMPOUND USED AS A P2X1 AND P2X3 RECEPTOR ANTAGONIST, A PRODUCTION METHOD FOR THE SAME AND A COMPOSITION COMPRISING THE SAME
申请人:Kim Yong-Chul
公开号:US20130040997A1
公开(公告)日:2013-02-14
Provided are a novel pyridine carboxylic acid based compound used as a P2X
1
and P2X
3
receptor antagonist, a production method for the same and a composition comprising the same. The compound according to the present invention is a powerful antagonist of P2X
1
and P2X
3
receptors, and hence can be used as a drug for treating or preventing diseases involving neurological pain or chronic inflammatory diseases which are diseases caused by P2X
1
and P2X
3
receptor activity.